HC Wainwright & Co. Reiterates Buy on Spruce Biosciences, Maintains $10 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Spruce Biosciences (NASDAQ:SPRB) and maintained a $10 price target.
August 18, 2023 | 10:24 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Spruce Biosciences' stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $10.
The reiteration of the 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in Spruce Biosciences. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100